Alampi MM, Kozlíková M, Mariangeli M, Civita S, Delcanale P, Mussini A, Diaspro A, Bianchini P, Weyergang A, Skarpen E, Berg K, Viappiani C, Abbruzzetti S, Selbo PK (2025) Light-enhanced cytotoxicity and intracellular trafficking of the PD-L1-targeting photoimmunoconjugate EITC-atezolizumab. Biomed Pharmacother 191:118550. doi: 10.1016/j.biopha.2025.118550 PMID: 40946581
Objective: To optimize the cytotoxic efficacy of a photoimmunoconjugate of eosin-5-isothiocyanate and atezolizumab (EITC-atezolizumab) in NSCLC cells; To study the uptake and intracellular transport of atezolizumab; and to evaluate EITC-atezolizumab as a candidate for photochemical internalization (PCI) of the ribosome-inactivating protein gelonin.
Summary: This is the first documentation demonstrating that atezolizumab is transported to CD63-positive organelles, thereby enhancing our understanding of its intracellular trafficking. The study also strengthens the concept of Photoimmunotherapy (PIT) and atezolizumab-based targeting of PD-L1+NSCLCs.
Usage: The cytotoxic efficacy of the PD-L1-targeting immunotoxin (Anti-PD-L1-SAP) was strongly enhanced in PD-L1-positive breast cancer cells by photochemical internalization (PCI),a low-dose, Photodynamictherapy (PDT)-based intracellular drug delivery method.
Related Products: Anti-PD-L1-SAP (Cat. #IT-45)